By Jonathan Stempel NEW YORK, July 21 (Reuters) - Amgen reached a $74 million settlement of a lawsuit accusing the ...
Amgen has agreed to a $74 million settlement with investors who allege that the company hid a massive U.S. tax bill from the ...
A recent court decision blocking Colorado’s planned 70% price cap on Enbrel has removed a key regulatory overhang for Amgen ...
Colorado is one of a handful of states with a review board for drug prices and one of only four with a board empowered to set ...
By Puyaan Singh June 29 (Reuters) - The New England Journal of Medicine on Monday retracted an article on a pivotal clinical trial that supported approval of Amgen’s rare-disease drug, citing concerns ...
The Cool Down on MSN
Amgen recalls nearly 1 million U.S. bottles of heart drug Corlanor over possible contamination
Tests found that the foreign matter does not pose a clinical risk to patients.
Barchart on MSN
Amgen earnings preview: What to expect
Thousand Oaks, California-based Amgen Inc. (AMGN) is a leading independent biotechnology company that discovers, develops, ...
Zacks.com on MSN
Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Amgen (AMGN) closed at $355.25, marking a -1.44% move from the previous day. The stock's ...
Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
Amgen has reacted with consternation to the news that treatment with its KRAS inhibitor Lumykras will no longer be funded in ...
Amgen will employ the Veeva Clinical Platform to support and identify efficiencies across the clinical trial process. "We're excited to help Amgen further advance clinical development. Veeva Clinical ...
A clinical trial used to approve Amgen Inc.’s pill Tavneos was retracted Monday from the New England Journal of Medicine, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results